A B S T R A C T The cardiovascular responses elicited by dobutamine are distinctly different from those produced by other adrenergic or dopaminergic agonists. To test the hypothesis that dobutamine could have differential affinities for adrenergic receptor subtypes, and that such subtype selectivity could be related to its relatively unique pharmacologic properties, we assessed the ability of dobutamine to displace adrenergic radioligands from membrane receptors in a number of tissues of previously characterized adrenergic receptor subtype. For beta adrenergic receptors identified by (-) [3H]dihydroalprenolol (DHA), dobutamine had significantly greater affinity for the ,f3 subtype (KD = 2.5 MM in rat heart and 2.6 MM in turkey erythrocyte) than for the (82 subtype (KD = 14.8 AM in frog heart and 25.4 ,uM in rat lung) (P < 0.001). For alpha adrenergic receptors, dobutamine had markedly greater affinity for the a,-subtype identified by [3H]prazosin (KD = 0.09 ,uM in rat heart and 0.14 AM in rabbit uterus) than for the a2-subtype identified by [3H]dihydroergocryptine (DHE) (KD = 9.3 MuM in human platelet) or by [3H]-yohimbine (KD = 5.7 MM in rabbit uterus) (P < 0.001).
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Like other 3B,-agonists, in the absence of guanine nucleotide, dobutamine competition curves for DHA binding in rat heart demonstrated two classes of binding sites, with one site of significantly higher affinity (KD = 0.5 MM, P = 0.008) than the single class of binding sites (KD = 5.2 MuM) identified in the presence of guanine nucleotide. However, unlike /32-or a2-agonists, dobutamine displacement of DHA binding in rat lung or of DHE binding in human platelets demonstrated only a single class of binding sites, and guanine nucleotide had only minimal effects.
INTRODUCTION
The pharmacologic effects produced by infusions ofthe synthetic catecholamine dobutamine differ from those elicited by other adrenergic agonists. At doses producing equivalent enhancement of cardiac inotropy, dobutamine induces a smaller positive chronotropic effect than isoproterenol. In addition, dobutamine induces neither the vasodilatory effects of isoproterenol or epinephrine, which are mediated through vascular beta adrenergic receptors, nor the vasoconstrictive effects of norepinephrine on arteriolar resistance vessels, mediated through vascular alpha adrenergic receptors. Furthermore, dobutamine is reportedly devoid of the presynaptic effects on endogenous norepinephrine release exhibited by its parent compound dopamine and by other adrenergic agonists (1) (2) (3) (4) .
The pharmacologic properties of dobutamine that account for its unique spectrum of hemodynamic effects have not been previously elucidated. One tenable hypothesis is that dobutamine may bind selectively to specific subtypes of alpha and beta adrenergic receptors, and that such selective binding could be causally related to its distinctive pharmacologic effects. The original division of biologic responses to catecholamines into two categories, alpha and beta, based on the relative potencies ofadrenergic compounds in eliciting (or blocking) specific physiologic effects (5) has been extended in recent years by further subclassification of both beta adrenergic (6) and alpha adrenergic (7) responses. Since current concepts of adrenergic agonist and antagonist action suggest that the specificity of biologic responses to adrenergic agents resides in the nature of the sarcolemmal adrenergic receptors, radioligand binding studies have proven to be a useful complement to physiologic measurements in determining the subclassification ofadrenergic receptors (8) (9) (10) (11) . Furthermore, recent insights into the important regulatory function of guanine nucleotides in the coupling of adrenergic agonist binding to the subsequent biochemical and physiologic sequelae of receptor activation have expanded the role of radioligand binding methods in assessing the molecular pharmacology of adrenergic compounds. At least for 8l-, 12-, and a2-receptors, the ability to form a high affinity ligand-receptor complex which is shifted to a lower affinity state by guanine nucleotides is directly correlated with the intrinsic activity (i.e., the maximum response produced by saturating concentrations of agonist) of adrenergic agonists in eliciting biochemical or physiologic responses. Guanine nucleotides produce a large shift in apparent affinity for full agonists and a smaller shift for partial agonists. Competitive binding curves for antagonist compounds are unaffected by guanine nucleotides (12) (13) (14) .
To test the hypothesis that dobutamine may bind selectively to specific subtypes of alpha and beta adrenergic receptors, we have assessed the ability of dobutamine to displace tritiated adrenergic ligands from both alpha and beta adrenergic receptors in a number of tissues in which the adrenergic receptor subtype specificity has been previously defined. In addition, as an indirect assessment of the specific activity of dobutamine for activation of responses mediated through specific adrenergic receptor subtypes, we have assessed the effect ofguanine nucleotides upon dobutamine binding in these selected tissues.
METHODS
Preparation ofmembrane homogenates. Rat cardiac membranes were prepared as described in previous publications from our laboratory (15) , and frog heart membranes were prepared in an identical fashion. Membrane fractions from human platelet, rabbit uterus, rat lung, and turkey erythrocyte were prepared with minor modifications of previously published techniques (10, (16) (17) (18) .
Radioligand binding experiments. In each radioligand binding experiment, aliquots of a given membrane preparation were incubated with a fixed concentration of radioligand in the presence ofvarying concentrations of dobutamine ranging from 1 nM to 1 mM. In addition, in each experiment, radioligand binding in the absence of added dobutamine, and in the presence of either 10 ,LM (t) propranolol (/3-receptors except lung), 10 tLM (+) propranolol (lung ,8-receptors), or 10 ,aM phentolamine (a-receptors) was used to define maximal binding and nonspecific binding, respectively. Lefkowitz.2 The sources of the other reagents used include the following: dobutamine (Eli Lilly and Co., Indianapolis, Ind.), phentolamine (Ciba Pharmaceutical Co., Summit, N. J.), (-) epinephrine, (-) isoproterenol, and (+) propranolol (Sigma Chemical Co., St. Louis, Mo.).
Protein was determined by the method of Lowry et al. (23) . Adenylate cyclase assay. We prepared human platelet lysates and assayed adenylate cyclase activity as previously described by Tsai and Lefkowitz (24) , with two exceptions: we utilized hypotonic lysis and mechanical homogenization for preparation of platelet lysates without freezing the membranes; and incubations were carried out for 10 min at 37°C. We assessed the intrinsic activities of (-) epinephrine, a compound known to be a full agonist at a2-receptors (24) , and of dobutamine by their respective abilities to inhibit the stimulation of adenylate cyclase elicited by 10 10 ,uM phentolamine (a-receptors) was set at 0%. The normalized binding values at each concentration of dobutamine from separate experiments were meaned, and the pooled doseresponse curves obtained in this fashion were utilized for all subsequent analyses.
Each competition curve was analyzed by a nonlinear leastsquares curve-fitting procedure employing a generalized model for complex ligand-receptor interactions and performed using an iterative program in PL/1 on a PDP 11/45 computer. Fitted parameter estimates were thus obtained for each competition curve. The details of this analytical method have been previously described (25) . To determine the significance between parameter estimates (such as KD) fronm two separate competition curves, each curve was first analyzed independently determining the KD estimates which provided the "best fit" of each separate dose-response curve. The curves were then analyzed simultaneously constraining the KD estimate for dobutamine competition for radioligand binding in curve 1 to be equivalent to the KD estimate for curve 2. The goodness of fit obtained by analyzing the data first independently, and then with this constraint, was assessed by measuring the residual variance between the data and each of the fitted curves, and comparing these variances by an F ratio test. For example, the KD estimated from dobutamine competition for radioligand binding in one tissue homogenate (A) would be considered significantly different from the KD estimated from dobutamine competition for radioligand binding in a different homogenate (B) when the residual variance of curves constraining KD (A) = KD (B) was increased significantly (by F test) from the residual variance observed when KD (A) and KD (B) were estimated independently.
RESULTS
We observed dobutamine to displace adrenergic radioligands from binding sites in each membrane preparation to an equivalent degree to the maximal inhibition produced by 10 Beta adrenergic subtype specificity. Dobutamine exhibited greater affinity for beta adrenergic receptors of the 8,3-than of the 182-subtype. The dissociation constants for dobutamine in membranes derived from rat heart and turkey erythrocytes, which are predominantly of the f31-subtype (8, 22) , were significantly lower than those observed in membranes derived from frog heart and rat lung, which contain predominantly ,32-receptors (8, 10) (Table II; Figs. 1 and 2 ). In addition, dobutamine competition curves in rat cardiac membranes quantitated in the absence of guanine nucleotide were best characterized by two classes of binding sites: a high affinity site (KD = 0.5 ,uM) representing 44% of the receptor population, and a lower affinity site (KD = 5 ,uM) representing the remaining 56% of the receptors present. In the presence of 0.1 mM GPP, only a single class ofbinding sites ofthe lower affinity (KD = 5.2 ,uM) was observed (Fig. 1) . The formation ofthis high affinity state, which is reversible by guanine nucleotide, is characteristic ofbeta adrenergic agonists in rat heart (8) . On the other hand, dobutamine competition curves to ,32-receptors of rat lung in the absence of guanine nucleotide were described best by only a single class of binding sites, and were shifted only minimally by 0.1 mM GPP. Shifts in agonist affinity for beta2 receptors of rat lung induced by guanine nucleotides have been previously well characterized (13) "Significance of rat heart (3) vs. human platelet and of rat heart (4) vs. platelet. membrane preparation (Fig. 2) . In a manner analogous to the observations in rat lung membranes, we observed in a single experiment no effect of 0.1 mM GPP on dobutamine competition curves for DHA binding in frog heart membranes (data not shown). Presumably because the preparation contains endogenous guanine nucleotide, the 813-receptors of crude (as opposed to highly purified) turkey erythrocyte membranes do not exhibit this shift in agonist affinities with the addition of guanine nucleotides (26) It should be noted that if one considers only the high affinity site for dobutamine binding to rat heart receptors observed in the absence of guanine nucleotides, the ,31-selectivity of dobutamine assessed by comparing its affinity for beta receptors of rat heart vs. rat lung or frog heart increases to >10-fold, from the 3-fold reported in Table II derived from published data (rat heart [8] , frog heart [8] , turkey erythrocyte [27] ), or determined in separate experiments (rat lung). The ratio ofKD dobutamine to KD (-) isoproterenol (in the presence of guanine nucleotide) in rat heart was 2.4 and was 2.8 in turkey erythrocyte, whereas this ratio was 7.1 in frog heart and 13.6 in rat lung. Alpha adrenergic subtype selectivity. Dobutamine exhibited greater affinity for alpha adrenergic receptors of the a,-subtype than of the a2-subtype. The dissociation constant for dobutamine in membranes derived from rat heart, which are predominantly et, (19) , was significantly lower than that observed in human platelet membranes, which are exclusively a2 (20) (Table II, Fig. 3 ). Since rabbit uterine membranes contain a mixture of al-and a2-receptors (20) Fig. 4 ).
Since guanine nucleotides influence agonist affinity at a2-receptors in an analogous manner to the changes observed at /,3-and /32-receptors (14), we studied the effects of0.1 mM GPP on dobutamine and (-) epinephrine binding to a2-receptors of human platelets. As seen in Fig. 5, (-) lacked this effect (Table III) . The EC50 for (-) epinephrine inhibition of PGE,-stimulated adenylate cyclase activity was 1.9 ,uM, paralleling its potency in the competitive binding assay (Fig. 5) . DISCUSSION The widely accepted view (28) that both chronotropic and inotropic responses to catecholamines are mediated exclusively through cardiac adrenergic receptors of the ,63-subtype has recently been challenged on two fronts. Persuasive evidence supporting the existence of functional postsynaptic cardiac alpha adrenergic receptors influencing both chronotropy and inotropy has been presented (15, (29) (30) (31) ; and some investigators have advanced the hypothesis that cardiac receptors of the 832-subtype may play a role in mediating chronotropic, but not'inotropic, responses to catecholamines. For example, Carlsson et al. (32) observed in a reserpinized anesthetized cat model that the ratio ofthe drug dose required to produce a 50% maximal chronotropic response to the dose required to produce a 50% maximal inotropic response was 0.93 for the 8,-selective agonist (-) H80/60, 0.5 for the non-subtype selective agonist (-) isoproterenol, and 0.16 for the p32-selective agonist terbutaline. Other authors have reported proportionately greater effects upon heart rate than upon contractility from 82-selective, as opposed to non-subtype selective or /31-selective agents in other experimental preparations (33) (34) (35) (36) (37) . induced by PGE1, which we observed in the presence of dobutamine, may reflect beta adrenergic agonist effects of dobutamine that are unopposed by a2-agonist effects. These small increases were blunted by 10 ,uM (±) propranolol.
Propranplol had no effect on the inhibition of PGE,-stimulated adenylate cyclase activity induced by (-) epinephrine, whereas this response was abolished by 10 ,uM phentolamine.
The relative lack of positive chronotropic effects of dobutamine compared with those produced by isoproterenol at doses of each compound eliciting equivalent positive inotropic effects has been demonstrated in clinical studies (2, 38, 39) , in both conscious and anesthetized dog models (1-4) and in some isolated heart preparations (1, 40) . Although other investigators have failed to observe an inotropic selectivity in isolated myocardial preparations (41, 42) , there is agreement that the inotropic selectivity of dobutamine in vivo is not fully attributable to baroreceptor influences, or to effects on endogenous norepinephrine release, degradation, or reuptake (1-3) .
By what mechanism, then, are the pharmacologic responses to dobutamine mediated? The relative selectivity of dobutamine for inotropic as opposed to chronotropic stimulation, when compared with (-) isoproterenol, renders untenable the hypothesis that both agents exert their direct cardiac effects exclusively through identical ,B,-receptors. An alternative hypothesis is that dobutamine is relatively selective for stimulation of /3-as opposed to /32-adrenergic receptors, and that the chronotropic responses to catecholamines are indeed mediated more by agonist binding to ,/2 than to ,B,-receptors. Our current data demonstrate a greater affinity of dobutamine for ,B,-than for ,82-receptors in vitro, and, by virtue of the minimal ability of dobutamine to form the high affinity agonist-receptor complex which is reversed by guanine nucleotide at 182-receptors in vitro, predict that dobutamine should have minimal stimulatory effects upon physiologic or biochemical responses mediated through ,82-receptors. Previous pharmacologic data confirm this prediction: dobutamine has only minimal effects upon peripheral B32-receptors mediating relaxation of vascular smooth muscle (1) (2) (3) (4) , and previous studies of biochemical responses to dobutamine have also suggested that this compound has little agonist activity at ,82-receptors. For example, Pike and Lefkowitz (43) found dobutamine to be a partial agonist for stimulation of adenylate cyclase or of GTPase activity in turkey erythrocyte membranes (i83) with peak stimulatory activity 24 and 19%, respectively, of that observed for (-) isoproterenol, whereas dobutamine had only minimal activity for stimulation of adenylate cyclase (8% of [-] (29) (30) (31) , perhaps direct al-agonist activity in the heart could account for dobutamine's distinctive effects. The work of Tuttle and Mills (1) suggested that dobutamine's inotropic effects were only minimally affected by phenoxybenzamine, but the effects of alpha blockade on the heart rate responses to dobutamine have not, to our knowledge, been reported. Since agonist binding to alreceptors does not appear to be markedly influenced by guanine nucleotides in rat heart3 and rabbit uterus (14) (45) . Studying blood pressure responses in pithed rats, these latter investigators have noted that the a1 selective antagonists phenoxybenzamine and dibenamine were considerably more potent in blocking the pressor effects of direct sympathetic stimulation than in blocking the effects of infused exogenous norepinephrine. The converse was true for the a2-antagonists mianserin and piperoxan. Citing the evidence for postsynaptic receptors of the a2-subtype in other tissues (7), they proposed that two subpopulations of postsynaptic alpha adrenergic receptors mediating vasoconstriction are present in peripheral blood vessels: a,-receptors localized to the region of the vascular neuro-effector junctions, and separate a2-receptors which are the most important sites of action of infused or humorally circulating alpha agonists. If this hypothesis is valid, and if such a distinction between "intrasynaptic" a, and "extrasynaptic" (44) a2 postsynaptic receptors of vascular smooth muscle is physiologically relevant, the relatively weak effects of infused dobutamine on vascular smooth muscle in vivo (1-4) would be predicted from our radioligand binding studies, which demonstrated a much greater affinity of dobutamine for al-as opposed to a2-receptors, regardless of whether dobutamine is an al-agonist or antagonist.
Since dobutamine clearly binds to both 132-and a2-receptors, yet exhibits only weak agonist effects, it would be expected, at appropriate concentrations, to function as an antagonist at receptors of these subtypes. [20] ). Nonetheless, it is plausible that antagonism of endogenous catecholamine effects mediated through ,2-or a2-receptors may influence the pharmacologic actions of dobutamine. Furthermore, 32-or a2-antagonist activity by dobutamine could alter the effects of 32-or a2-agonist drugs that might be utilized concurrently with dobutamine. These possibilities have not, to our knowledge, been rigorously tested in animal preparations or in man, and seem to merit further study.
In a previous report, Minneman et al. (47) have assessed the affinity of dobutamine for inhibition of
[1251]iodohydroxybenzylpindolol binding to f31-receptors of rat heart homogenates and to 132-receptors of rat lung homogenates; they concluded that no subtype selectivity of dobutamine was present. The explanation for the discrepancy between those findings and our results is not readily evident; however, the more highly detailed nature of our current competition curves, coupled with the prior physiologic and biochemical response data suggesting that dobutamine has only weak activity at 132-receptors, support the conclusion that dobutamine is indeed a 81-selective ligand.
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